The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children
Status:
RECRUITING
Trial end date:
2027-03-31
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized controlled crossover trial aimed to evaluate the efficacy and safety of dapagliflozin in the treatment of hereditary kidney disease with proteinuria in children
Phase:
PHASE3
Details
Lead Sponsor:
Children's Hospital of Fudan University
Collaborators:
Children's Hospital of Nanjing Medical University Children's Hospital of The Capital Institute of Pediatrics First Affiliated Hospital, Sun Yat-Sen University First People's Hospital of Urumqi Guangzhou Women and Children's Medical Center Guiyang Maternity and Child Health Care Hospital Kunming Children's Hospital Maternal and Child Health Care Hospital of Hainan Province Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region Second Affiliated Hospital of Wenzhou Medical University Shandong Provincial Hospital The Children's Hospital of Zhejiang University School of Medicine The First Affiliated Hospital of Henan University of Traditional Chinese Medicine The Second Hospital of Hebei Medical University Wuhan Children's Hospital Wuxi Women's & Children's Hospital Xiamen Women's and Children's Hospital Xian Children's Hospital Xuzhou Children Hospital Zhengzhou Children's Hospital, China